The regulation of hexokinase II (HKII) was examined in fat and skeleta
l muscle of an animal model of non-insulin-dependent diabetes mellitus
, the KKA(Y) mouse. These tissues require insulin for facilitated tran
sport of glucose and express the insulin-responsive transporter GLUT4.
The combined data from two experiments (n = 12 for each experimental
condition) demonstrated mean concentrations of plasma insulin in pmol/
l and glucose in mmol/l of 122 and 7.2 (control nondiabetic C57 mouse)
vs. 1,118 and 29.6 (diabetic mouse), respectively. The tissues of dia
betic mice compared with control mice demonstrated a reduction of HKII
mRNA abundance of 68% in epididymal fat (P = 0.0001) and 34% in the q
uadriceps muscles (P < 0.001), with concordant reduction in the abunda
nce of GLUT4 mRNA of 60% in epididymal fat (P < 0.001). In comparison
with the results in untreated diabetic mice, diabetic animals treated
with the insulin-sensitizing drug pioglitazone demonstrated an increas
e in the abundance of HKII mRNA with a concordant increase of GLUT4 mR
NA in epididymal fat (P = 0.03 and < 0.01, respectively), and an incre
ase of HKII mRNA in the quadriceps muscles (P < 0.05). Separate experi
ments demonstrated a reduction of HKII protein abundance by 61% in epi
didymal fat (P < 0.001, n = 12 for each experimental condition) and by
71% in the quadriceps muscles (P < 0.001, n = 6 for each experimental
condition). In comparison with untreated diabetic mice, there was an
increase in the abundance of HKII protein in epididymal fat of animals
treated with pioglitazone (P < 0.05). Additional experiments showed a
reduction of HKII protein activity in untreated diabetic mice of 24%
in the quadriceps muscles (P < 0.05, n = 6 for each experimental condi
tion). Because HKII deficits can be reversed, it appears that abnormal
expression of HKII may occur secondary to insulin resistance; neverth
eless such changes may exacerbate hyperglycemia.